AbbVie (ABBV) is suing the Trump administration to get a clearer definition of who counts as an eligible patient in the government’s discount drug program, Maya Goldman of Axios reports. AbbVie filed a lawsuit in the District Court for the District of Columbia, saying that definition is “overly inclusive, capturing individuals who may have had only a cursory encounter with the covered entity a long time ago,” according to the website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target lowered to $240 from $250 at Cantor Fitzgerald
- AbbVie’s Real‑World Parkinson’s Study in Belgium: What Investors Should Watch
- AbbVie should be bought on recent selloff, says JPMorgan
- AbbVie, Genentech to sell popular commercial drugs on TrumpRx, CBS says
- Oruka Therapeutics price target raised to $125 from $60 at Guggenheim